Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia
Authors' conclusion
Pasireotide effectively restored glucose levels in insulinoma patients who failed prior treatments. However, its efficacy was lower in aggressive insulinomas, emphasizing the need for alternative or combinatory strategies in metastatic cases. Given that pasireotide was never used as a first-line therapy in the reviewed cases, earlier administration in selected patients may improve outcomes.
Study context
- Population
- Patients with insulinoma-associated hypoglycemia; ages 52 to 71 years, 9 women; 5 (30%) underwent surgical tumor resection; pasireotide never the initial treatment
- Participants
- 17 patients13 studies
- Outcome
- Response of hypoglycemia to pasireotide
Methodological detailspredeveloped protocol, Searched MEDLINE, Scopus, Google Scholar and references from inception to March 30, 2024; 490 identified, 137 reviewed
- Predeveloped protocol
- Searched MEDLINE, Scopus, Google Scholar and references from inception to March 30, 2024; 490 identified, 137 reviewed
Pooled result
As reported in the abstract
No improvement
6
35%
Partial improvement
4
23%
Complete resolution
7
41%
Further pooled results
No improvement, by insulinoma behaviour
No improvement, by insulinoma behaviour
- Lower response rate in aggressive insulinomas
Tumor size and response
- Larger tumors significantly associated with poorer response
- P = 0.043
Safety
- Hyperglycemia, the most common side effect
- n = 3
Original publication
Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia. J Clin Endocrinol Metab. Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →